EWTX
Edgewise Therapeutics Inc
Edgewise Therapeutics Inc historical holders
total: 1
Viking Global Investors Edgewise Therapeutics Inc transactions over time
- Total transactions:
- 11
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 5
- Held since:
- 2021 Q1
- Held for:
- 17 quarters
- Latest activity:
- 2025 Q2
Ole Andreas Halvorsen has been an institutional investor in Edgewise Therapeutics Inc (EWTX) since 2021 Q1. According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any shares. The fund/company first acquired EWTX in 2021 Q1, initially purchasing about 3.35M shares. Since the initial investment, Viking Global Investors has made 10 more transactions in this position.
When did Ole Andreas Halvorsen exit their EWTX position?
Ole Andreas Halvorsen no longer holds Edgewise Therapeutics Inc (EWTX). They sold off their entire position in 2025 Q2, closing out an investment that began in 2021 Q1.
When did Ole Andreas Halvorsen first invest in EWTX?
Ole Andreas Halvorsen first invested in Edgewise Therapeutics Inc (EWTX) in 2021 Q1 at the reported quarter-end price of $32.50 per share, acquiring 3,352,249 shares in their initial purchase.
What is Ole Andreas Halvorsen's average cost basis for EWTX?
Based on historical transaction data, Ole Andreas Halvorsen's estimated cost basis for Edgewise Therapeutics Inc (EWTX) is approximately $20.35 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $20.35
- Weighted AVG sell price:
- $19.46
EWTX transactions history by Viking Global Investors
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q2
|
0.00%
|
0
|
$22.00
|
|
-100% (-490,035)
|
-0.03%
|
|
2025 Q1
|
0.03%
|
490,035
|
$22.00
|
$10,780,770
|
-60.00% (-734,951)
|
-0.05%
|
|
2024 Q4
|
0.11%
|
1,224,986
|
$26.70
|
$32,707,126
|
-17.29% (-256,160)
|
-0.02%
|
|
2024 Q2
|
0.10%
|
1,481,146
|
$18.01
|
$26,675,439
|
-55.64% (-1,858,000)
|
-0.12%
|
|
2024 Q1
|
0.23%
|
3,339,146
|
$18.24
|
$60,906,023
|
-45.79% (-2,820,000)
|
-0.19%
|
|
2023 Q3
|
0.14%
|
6,159,146
|
$5.73
|
$35,291,907
|
+3.63% (+215,885)
|
+0.01%
|
|
2023 Q2
|
0.19%
|
5,943,261
|
$7.75
|
$46,060,273
|
+21.07% (+1,034,115)
|
+0.03%
|
|
2023 Q1
|
0.15%
|
4,909,146
|
$6.67
|
$32,744,004
|
+11.34% (+500,000)
|
+0.02%
|
|
2022 Q3
|
0.20%
|
4,409,146
|
$9.84
|
$43,386,000
|
+61.67% (+1,681,897)
|
+0.08%
|
|
2021 Q2
|
0.18%
|
2,727,249
|
$21.33
|
$58,172,000
|
-18.64% (-625,000)
|
-0.04%
|
|
2021 Q1
|
0.32%
|
$32.50
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.